未登录

F

Fakhrul Ahsan

Oakland University

H指数:41

被引数:5,845

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis

奈兰司特作为特发性肺纤维化的第一种PDE4B-selective疗法

Trends in Pharmacological Sciences

IF19.9

2025-12-060

PRE

Image cytometry-based quantification protocol of human pulmonary arterial endothelial cells in lab-fabricated multichannel microfluidic devices

IF1.3

2025-10-010

OAAI

Investigation of the role of Cremophor RH 40 and Cremophor EL in the inhibition of efflux pump of Pseudomonas aeruginosa

IF3.6

2024-07-010

OAAI

Development of a bladder cancer-on-a-chip assay to assess the invasive potential of bladder cancer cells

CANCER RESEARCH

IF16.6

2024-04-050

PRE

Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension

PHARMACEUTICALS

IF4.8

2023-11-280

OAAI

An evolving perspective on novel modified release drug delivery systems for inhalational therapy

EXPERT OPINION ON DRUG DELIVERY

IF5.4

2023-02-1611

OA

Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance

AAPS PHARMSCITECH

IF4

2022-09-1917

PRE

A Protocol for Fabrication and on-Chip Cell Culture to Recreate PAH-Afflicted Pulmonary Artery on a Microfluidic Device

IF3

2022-09-076

OAAI

Physical stability and dissolution behaviors of amorphous pharmaceutical solids: Role of surface and interface effects

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2022-09-0117

PRE

Multilayer Soft Photolithography Fabrication of Microfluidic Devices Using a Custom-Built Wafer-Scale PDMS Slab Aligner and Cost-Efficient Equipment

IF3

2022-08-2020

OAAI

Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension

IF3.9

2022-01-1320

OAAI

Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

IF3.5

2021-06-018

OA

Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension

EXPERT OPINION ON DRUG DELIVERY

IF5.4

2020-02-1933

OAAI

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application

IF5.4

2020-01-0122

OAAI

Digital light processing (DLP) 3D-printing technology and photoreactive polymers in fabrication of modified-release tablets

数字光处理 (DLP) 3d打印技术和光反应性聚合物在缓释片制备中的应用

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2019-07-01185

PREAI

Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

IF3.5

2019-01-0119

OAAI

Multi-purposable filaments of HPMC for 3D printing of medications with tailored drug release and timed-absorption

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2018-06-01116

PREAI

Low-Molecular-Weight Heparin-Coated and Montelukast-Filled Inhalable Particles: A Dual-Drug Delivery System for Combination Therapy in Asthma

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2017-04-0115

PREAI

Systemically Administered, Target-Specific Therapeutic Recombinant Proteins and Nanoparticles for Regenerative Medicine

ACS BIOMATERIALS SCIENCE & ENGINEERING

IF5.5

2017-01-2413

OAAI

De-clotting tumor to improve the perfusion, distribution and efficacy of chemotherapy and nanotherapeutics

CANCER RESEARCH

IF16.6

2017-01-160

PRE